Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor
about
The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsiaThe complement system and adverse pregnancy outcomesAngiogenic factors in diagnosis, management, and research in preeclampsia.Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry.Molecular mechanisms of preeclampsia.The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome.Relation between maternal angiogenic factors and utero-placental resistance in normal first- and second-trimester pregnancies.Maternal endothelial progenitor colony-forming units with macrophage characteristics are reduced in preeclampsia.Expression of placental growth factor mRNA in preeclampsia.The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.Dysregulation of promyelocytic leukemia (PML) protein expression in preeclamptic placentae.Maternal circulating CD34+VEGFR-2+ and CD133+VEGFR-2+ progenitor cells increase during normal pregnancy but are reduced in women with preeclampsia.Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery.Pregnancy-induced hypertension and preeclampsia: levels of angiogenic factors in malaysian womenThe vascular endothelial growth factor family in adverse pregnancy outcomes.Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia.Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.Angiogenic and inflammatory biomarkers in midpregnancy and small-for-gestational-age outcomes in Tanzania.Circulating angiogenic and antiangiogenic factors in women with eclampsia.Peptidomic Identification of Serum Peptides Diagnosing PreeclampsiaComparison of placental growth factor and fetal flow Doppler ultrasonography to identify fetal adverse outcomes in women with hypertensive disorders of pregnancy: an observational studyPolymorphisms in maternal and fetal genes encoding for proteins involved in extracellular matrix metabolism alter the risk for small-for-gestational-age.Synergistic effect of gestational hypertension and postpartum incident hypertension on cardiovascular health: a nationwide population study.Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction.Induction of heme oxygenase-1 attenuates sFlt-1-induced hypertension in pregnant rats.The Impact of Magnesium Sulfate Therapy on Angiogenic Factors in Preeclampsia.Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy.Prediction of Fetal Growth Restriction by Analyzing the Messenger RNAs of Angiogenic Factor in the Plasma of Pregnant Women.Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methodsThe placenta in preeclampsia.Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice.A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsiaTiming of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat.Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products.Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnanciesAngiogenic factors in preeclampsia and related disordersPlacental Complications and Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort StudyCXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsiaAlterations in polyadenylation and its implications for endocrine disease.
P2860
Q26798193-21B32C5F-5A64-4A11-9F15-E613D71F44A1Q26863600-487C8F58-B640-431A-B3D0-4D930DEEAD88Q27692060-EFA1E4AD-D111-406B-8D05-AC245BC6D086Q33329370-4CDEECE8-434F-4995-8843-51FB8BE84E49Q33344105-536516A8-EB41-46F8-B22E-166085BFD543Q33385942-B169C4A9-4157-436A-A8CA-AD895F0A59C6Q33667332-2AB1A870-37FC-4C9C-9653-219012DE3B3EQ33698023-449C02C6-6660-444E-B405-50003CD1EEE9Q33736940-7E81E66C-FDE7-4F31-96D2-41D6565925ECQ33755648-0B812509-9E2A-4F9B-B337-5FA78E6897B4Q33801203-2AC312FD-3647-404C-8598-89159416F4C5Q33945532-5842C610-C438-4541-BDA1-A519AAE4A94DQ34116772-1BEC38B6-E6F0-4175-9794-E7A2720FC01AQ34255236-B848D890-F80A-485F-A066-529B4F806615Q34267491-71527FDA-EB74-4EE8-A858-8B722D738627Q34481322-89B25865-9A77-4D71-AC36-FE51E97503ACQ34500006-62FB6950-2135-4020-BB88-DE68BDDF88E9Q34587814-308A1D31-3603-4362-ADAA-C6B0223562C9Q34670638-1895C406-68ED-46B7-9AE8-420E9C92DB83Q34804556-B0F73DEE-46B0-4716-9B72-0A1E0883FAFDQ34929017-B9ACDD15-9817-4D47-8DF3-0BBECB8763D1Q35015398-503E5560-F073-49E3-A9F7-6BB036CA3FF2Q35114857-E564B0F8-2FB2-49BE-B9FD-371185E82C36Q35426799-AF59E682-F3DC-4144-9287-C16EE9076573Q35543410-F6C7B3A2-C2CC-4AFA-AC0A-9E8262015C68Q35661796-0AFB7675-35A5-4462-89DE-B7A3520AAABAQ35699115-D28CE3F9-3FFD-4424-A1B3-FD0AC53CF433Q35853166-DA8B8533-9171-46D9-986D-6E51C240D5CBQ35886564-09FC67F5-B6E2-412C-B482-BE16C2E803F1Q36053252-5AE6390D-31B4-472B-B82E-886FD4495537Q36185056-275D496A-A9CE-4C3A-9E39-F65C510B8F57Q36189562-C0AA819F-7EF4-45BC-ACD4-91CE81D7857AQ36309225-07945386-27B3-48AC-978F-0983A08DCC4EQ36351625-D4F0A839-9CB9-47FF-BC7C-EF4F70189952Q36512063-401B530A-5510-4C53-8B34-055CA8F24A21Q36526596-31075CF2-1112-421F-AFA6-1AC57CAA8F31Q36630755-D4610162-ADC9-4E3E-B340-5D533664221AQ36676660-A734A220-1762-4FA7-8B27-DDAD99EEA839Q36772545-D62ECBA2-57AC-483B-A3BD-6FB795DF5051Q36824347-389B2EBF-681A-4FA5-B728-FCC25B39C7DB
P2860
Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor
description
article
@en
im August 2005 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2005
@uk
ലേഖനം
@ml
name
Soluble fms-Like Tyrosine Kina ...... lating Placental Growth Factor
@en
Soluble fms-Like Tyrosine Kina ...... lating Placental Growth Factor
@nl
type
label
Soluble fms-Like Tyrosine Kina ...... lating Placental Growth Factor
@en
Soluble fms-Like Tyrosine Kina ...... lating Placental Growth Factor
@nl
prefLabel
Soluble fms-Like Tyrosine Kina ...... lating Placental Growth Factor
@en
Soluble fms-Like Tyrosine Kina ...... lating Placental Growth Factor
@nl
P2093
P356
P1476
Soluble fms-Like Tyrosine Kina ...... lating Placental Growth Factor
@en
P2093
Augustine Rajakumar
Carol Gilmour
Eiji Shibata
James M. Roberts
Robert W. Larkin
Robert W. Powers
Roberta B. Ness
William R. Crombleholme
P304
P356
10.1210/JC.2004-1955
P407
P577
2005-08-01T00:00:00Z